Conferences - Results from #160

ESMO 2021: Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide Added to ADT Compared to ADT Alone for Men With High-Risk Non-Metastatic Prostate Cancer: Combined Analysis From Two Comparisons in the STAMPEDE Platform September 19, 2021

ESMO 2021: Pembrolizumab vs Placebo As Adjuvant Therapy for Patients With Renal Cell Carcinoma: Patient-Reported Outcomes in KEYNOTE-564 September 19, 2021

ESMO 2021: Nivolumab in Combination With Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients With Advanced RCC: A Randomized Phase II Trial (PRISM) September 19, 2021

ESMO 2021: Subsequent Therapy Following Pembrolizumab + Axitinib or Sunitinib Treatment for Advanced RCC in the Phase 3 KEYNOTE-426 Study September 19, 2021

ESMO 2021: First-Line Nivolumab + Cabozantinib vs Sunitinib in Patients With Advanced RCC in Subgroups Based on Prior Nephrectomy in the CheckMate 9ER Trial September 19, 2021

ESMO 2021: Pembrolizumab Monotherapy As First-Line Therapy in Advanced Non–Clear Cell RCC: Results After a Minimum of 34 Months of Follow-Up From KEYNOTE-427 Cohort B September 19, 2021

ESMO 2021: Matching-Adjusted Indirect Comparison of Health-Related Quality of Life of Nivolumab plus Cabozantinib Versus Pembrolizumab plus Axitinib in Previously Untreated Advanced RCC September 19, 2021

ESMO 2021: Pembrolizumab Monotherapy as First-Line Therapy in Advanced Clear Cell RCC: Results After a Minimum of 41 Months of Follow-up From KEYNOTE-427 Cohort A September 19, 2021

ESMO 2021: Role of Prior Nephrectomy for Synchronous Metastatic RCC on Efficacy in Patients Treated with Avelumab + Axitinib or Sunitinib: Results from JAVELIN Renal 101 September 19, 2021

ESMO 2021: Discussion on the Final Overall Survival Analysis From the ARCHES Study: Enzalutamide + ADT in Men With mHSPC September 19, 2021

ESMO 2021: Discussion on the PRINCE Trial of 177Lu-PSMA-617 in Combination With Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer September 19, 2021

ESMO 2021: Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor, Plus Cabozantinib for Treatment of Advanced Clear Cell RCC September 19, 2021

ESMO 2021: Antibiotic Therapy and Outcome from Nivolumab in Metastatic RCC Patients: Results of the GETUG-AFU 26 NIVOREN Multicentric Phase II Study September 19, 2021

ESMO 2021: A Prospective Phase II Trial of Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors: The CABA-GCT Study September 19, 2021

ESMO 2021: A Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Duct Renal Cell Carcinoma: The BONSAI Trial September 18, 2021

ESMO 2021: A Prospective Phase II Trial of Cabazitaxel in Male Patients with Chemotherapy Pre-Treated Metastatic Germ-Cell Tumors: The CABA-GCT Study September 18, 2021

AIBCCR 2021: Role of Immunotherapy (IO) in Urothelial Cancer September 18, 2021

ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer: AURA Trial September 18, 2021

ESMO 2021: Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer September 18, 2021

ESMO 2021: High- Versus Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer: NABUCCO Cohort 2 September 18, 2021

Page 9 of 429

email news signup